Rapid Micro Biosystems, Inc. (Nasdaq: RPID) reported its financial results for the third quarter ended September 30, 2026, and announced a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany.

For the third quarter of 2026, the company reported total revenue of $9.5 million, representing a 22% increase compared to the third quarter of 2025. This growth was driven by both the Product and Service segments. Specifically, Product revenue increased 24.9% to $6.5 million, while Service revenue increased 14.9% to $3.0 million. The company also noted that it placed seven new Growth Direct systems and completed 12 validations during the quarter.

The company achieved a record third quarter gross margin of 25.2%, or $2.4 million, a significant increase from 8.9%, or $0.7 million, in the prior year period. This expansion was driven by a 19 percentage point increase in Product gross margin to 12% and a 14 percentage point increase in Service gross margin to 54%.

Despite the revenue growth, the company reported a net loss of $11.3 million for the third quarter of 2026, or $0.23 per share, compared to a net loss of $11.5 million, or $0.26 per share, in the same period of 2025. Non-GAAP adjusted EBITDA loss for the quarter was $7.9 million, an improvement from a loss of $9.4 million in the prior year.

In a separate announcement, Rapid Micro stated that it has signed a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany. Under the terms of the agreement, Merck KGaA will acquire all outstanding shares of Rapid Micro Biosystems. As a result of the acquisition announcement, the company stated it will not host a conference call to discuss its financial results and is withdrawing its full year 2026 guidance. Additionally, the company will delay the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, to allow for the completion of certain financial reporting and disclosure matters related to the transaction.